At The Mark Foundation Center for Immunotherapy, Immune Signaling, and Radiation at the University of Pennsylvania, multidisciplinary collaboration is driving meaningful research progress.

The trial marks the first time the technology, conformal FLASH proton therapy, is being tested in humans. The hope, ultimately, is to preserve quality of life in patients by reducing side effects.

Ovarian cancer is notoriously difficult to detect early, with most patients diagnosed only once the disease has spread throughout the abdomen. At this advanced stage, treatment options are limited and...

Cancer therapies aim to kill tumor cells, but many instead establish a state of cell cycle arrest known as therapy-induced senescence (TIS). Paradoxically, TIS may provide an escape route for tumor…

CDK4/6 inhibition redirects Rb chromatin occupancy to activate oestrogen-responsive genes, counteracting its own ability to maintain therapeutic cell-cycle arrest.

Researchers at Peter Mac have discovered why breast cancer treatment stops working for some patients, uncovering the unexpected role of one of the body's most important cancer-fighting proteins.

Scientists are getting closer to understanding the wasting and fatigue that often accompanies cancer. Treatments could be on the horizon.

Pancreatic ductal adenocarcinoma is the third leading cause of cancer-related death in the United States, largely because most patients are diagnosed only after the disease has reached an advanced…

Experts hail daraxonrasib as ‘gamechanger’ for patients with advanced pancreatic cancer

YouTube video by Stanford Department of Medicine

Q&A with Steven Corsello, MD, on a new approach to treating pancreatic cancer.

Exciting new work from K. Christopher Garcia, co-investigator on MATCHMAKERS 👏   The study published in Nature Biotechnology shows that deep peptide-recognition profiling, combined with machine learni...

Opposing oncogenic and tumor-suppressive forces establish a progenitor-like state that builds a self-reinforcing niche to drive benign-to-malignant transition in pancreatic cancer models. Disruption o...

DNA-sequencing data from primary tumours and paired metastases from participants in the TRACERx lung study and PEACE autopsy programme are used to analyse the metastatic diversity of advanced non-smal...

Each year, the American Association for Cancer Research (AACR) convenes researchers at the leading edge of oncology at its Annual Meeting. This year, the Mark Foundation for Cancer Research is proud…

NMDAR expression is sufficient to induce B cell recruitment and affinity maturation, resulting in receptor-modulating antibodies that connect anti-cancer immunity and autoimmunity.

NEW YORK, NY – March 25, 2026 – The Mark Foundation for Cancer Research today announced a major evolution of its flagship Emerging Leader Award (ELA) program, significantly increasing its financial…